

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PODESTA GROUP, INC

2. Address:

1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

4. Contact Name: KIMBERLEY FRITTS

Telephone: 2023931010

E-mail (optional): LOBBYING@PODESTA.COM

Senate ID #: 31680-1002798

House ID #: 31110

7. Client Name: ☐ Self

MATTOON & ASSOC, LLC

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 40,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H. Con. Res. 99, Budget Resolution, drug importation provisions S. Con. Res. 21, Budget Resolution, drug importation provisions S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare, healthcare, and drug pricing provisions H. R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare, healthcare, and drug pricing provisions H. R. 2638, Homeland Security Appropriations Act, drug importation provisions S. 1644, Homeland Security Appropriations Act, drug importation provisions H. R. 2641, FY08 Energy & Water Appropriations S. 1751, FY08 Energy & Water Appropriations S. 1745, Departments of Commerce and Justice, Science, and Related Agencies Appropriations Act, DEA drug importation language H. R. 3093, Departments of Commerce and Justice, Science, and Related Agencies Appropriations Act, DEA drug importation language

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: MORRA, ELIZABETH

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S. 1145, Patent Reform Act of 2007, entire bill H. R. 1908, Patent Reform Act of 2007, entire bill

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare/Medicaid, healthcare, and drug pricing provisions
H. R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare/Medicaid, healthcare and drug pricing provisions

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H. R. 3162, CHAMP Act, Medicare cuts to finance SCHIP expansion S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion Possible DRA technical language H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions H. Con. Res. 99, Budget Resolution, Medicare/Medicaid provisions S. Con. Res. 21, Budget Resolution, Medicare/Medicaid provisions SCHIP (Senate), Medicare cuts to finance SCHIP expansion

17. House(s) of Congress and Federal agencies contacted:
Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 484, Enhancing Drug Safety and Innovation Act of 2007, clinical trials/drug safety provisions S. 993, Pediatric Research Improvement Act, clinical trials/drug safety provisions S. 1024, Safer DATA Act, clinical trials/drug safety provisions H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, PDUFA/drug safety S. 1082, Prescription Drug User Fee Amendments of 2007, PDUFA/drug safety H. R. 2900, Food and Drug Administration Revitalization Act, PDUFA/drug safety S. 623, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 1156, Best Pharmaceuticals for Children Amendments, pediatric exclusivity provisions in FDARA/PDUFA bill S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, drug importation provisions H. R. 1585, National Defense Authorization Act, drug pricing provisions S. 1547, National Defense Authorization Act, drug pricing provisions S. 467, FACT Act, clinical trials/drug safety provisions

17. House(s) of Congress and Federal agencies contacted:
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 07, 2007

Printed Name and Title: KIMBERLEY FRITTS, CEO -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

HCR

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 07, 2007

Printed Name and Title: -